Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours

  • N. D. Gay Knight Cancer Institute, Oregon Health and Science University
  • D. Tao Knight Cancer Institute, Oregon Health and Science University
  • V. Prasad Knight Cancer Institute, Center for Health Care Ethics, Oregon Health and Science University

Abstract

-

Author Biographies

N. D. Gay, Knight Cancer Institute, Oregon Health and Science University
Division of Hematology and Medical Oncology
D. Tao, Knight Cancer Institute, Oregon Health and Science University
Division of Hematology and Medical Oncology
V. Prasad, Knight Cancer Institute, Center for Health Care Ethics, Oregon Health and Science University
Division of Hematology and Medical Oncology, Department of Preventive Medicine and Public Health
Published
2019-12-20
How to Cite
Gay, N. D., Tao, D., & Prasad, V. (2019). Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. Current Oncology, 26(6). https://doi.org/10.3747/co.26.4845
Section
Letter to the Editor